Press Releases Merck KGaA

Equities

MRK

DE0006599905

Real-time Estimate Tradegate Other stock markets 03:31:05 2024-07-04 am EDT			5-day change	1st Jan Change
151 ^EUR	-0.13%		-2.93%	+4.79%

Jul. 01	Dawn Health and Merck Collaborate to Support Growth Disorders Care	CI
Jun. 27	Chemicals collective agreement: Bonus days for union members	DP

Press Releases

Unlock all the news: Be the first to know and act before the market!

100% Free Registration

Merck KGaA: Phase III trials of xevinapant in locally advanced head & neck cancer discontinued	Jun. 24	EQ
Merck : Q1 24 Financial Statement	May. 16	PU
Merck : Q1 24 Earnings Presentation	May. 16	PU
Merck : Q1 24 Quarterly statement	May. 14	PU
Caris Life Sciences Announces Partnership with Merck KGaA, Darmstadt, Germany to Discover Novel Cancer Targets and Accelerate First-In-Class Antibody Drug Conjugate Development	Apr. 05	AQ
Merck's Corporate Venture M Ventures Arm Backs Nucleai to Advance Its First-in-class Spatial AI Biomarker in Active Clinical Enrollment	Apr. 04	AQ
Merck : Prospectus - C-029771	Mar. 28	PU
DD: Merck KGaA: Dr. Matthias Heinzel, buy	Mar. 27	EQ
DD: Merck KGaA: Peter Guenter, buy	Mar. 27	EQ
Merck KGaA, Darmstadt, Germany, Invests More than EUR 300 Million in New Life Science Production Site in Korea	Mar. 21	AQ
AFR: Merck KGaA: Preliminary announcement of the publication of financial reports according to Articles 114, 115, 117 of the WpHG [the German Securities Act]	Jan. 25	EQ
AFR: Merck KGaA: Preliminary announcement of the publication of quarterly reports and quarterly/interim statements	Jan. 25	EQ
Biocytogen Launches RenBiologics, a Sub-Brand Focused on Out-Licensing Fully Human Antibodies for Therapeutic Development	Jan. 24	AQ
Inspirna Partners with Merck KGaA, Darmstadt, Germany, to Accelerate Global Development of Ompenaclid	Jan. 05	AQ
Merck KGaA: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution	Dec. 13	EQ
Merck KGaA: Phase III trial results for evobrutinib in relapsing multiple sclerosis did not meet primary endpoint of reducing annualized relapse rates (ARR) compared to oral teriflunomide	Dec. 05	EQ
Merck KGaA: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution	Nov. 27	EQ
Merck KGaA: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution	Nov. 24	EQ
Veeva European Commercial Summit Gathers Life Sciences Industry Leading the Next Generation of Commercial Excellence	Nov. 23	AQ
Merck KGaA: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution	Nov. 22	EQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Headlines

MERCK : A lower starting point for future growth

May 27, 2024 at 03:36 am EDT

Merck KGaA : A European big pharma with positive momentum

January 20, 2023 at 05:51 am EST